Investors’ Patience Is Being Tested Right Now By Black Diamond Therapeutics Inc (NASDAQ: BDTX)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

Black Diamond Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $4.47 and fluctuated between $4.4950 as its day high and $3.9100 as its day low. The current market capitalization of Black Diamond Therapeutics Inc is $230.83M. A total of 1.74 million shares were traded on the day, compared to an average of 512.68K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BDTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 1 SELLs from insiders. Insiders purchased 5,120,832 shares during that period but sold 25,000.

In the most recent transaction, BIOTECH GROWTH N V bought 400,000 shares of BDTX for 2.34 per share on Oct 17. After the transaction, the 10% Owner now owns 8,517,839 company shares. In a previous transaction on Jul 05, Behbahani Ali bought 1,000,000 shares at 5.00 per share. BDTX shares that Director owns now total 4,448,757.

Among the insiders who bought shares, RA CAPITAL MANAGEMENT, L.P. acquired of 935,850 shares on Jul 05 at a per-share price of $5.00. This resulted in the Director holding 3,213,828 shares of BDTX after the transaction. In another insider transaction, BIOTECH GROWTH N V bought 1,000,000 shares at $5.00 per share on Jun 30. Company shares held by the 10% Owner now total 8,117,839.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BDTX in the last 3 months, the mean price target is $10.50 with high estimates of $11.00 and low estimates of $10.00. In terms of 52-week highs and lows, BDTX has a high of $6.85 and a low of $1.22.

As of this writing, BDTX has an earnings estimate of $USD/BDT per share for the current quarter. EPS was calculated based on a consensus of BioNTech SE estimates, with a high estimate of $BioRestorative Therapies, Inc. per share and a lower estimate of $Biodexa Pharmaceuticals plc.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BDTX’s latest balance sheet shows that the firm has $209.79M in Cash & Short Term Investments as of fiscal 2021. There were $28.46M in debt and $23.64M in liabilities at the time. Its Book Value Per Share was $2.60, while its Total Shareholder’s Equity was $195.90M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BDTX is Buy with a score of 5.00.

Most Popular

Related Posts